Properties
Description
Amuvatinib hydrochloride primarily acts by blocking the ATP-binding site of the kinase domain of the RET protein, thereby inhibiting its autophosphorylation. It targets c-Kit (D816H), c-Kit (D816V), c-Kit (V560G), c-Kit (V654A), PDGFRα (D842V), and PDGFRα (V561D).
Molecular Formula
C23H21N5O3S.xHCl
Targets
c-Kit (D816H): 10 nM; c-Kit (D816V): 950 nM; c-Kit (V560G): 34 nM; c-Kit (V654A): 127 nM; PDGFRα (D842V): 81 nM; PDGFRα (V561D): 40 nM
Identity
Confirmed by NMR/HPLC/MS.
Stability
The product is stable for three years when stored at the recommended temperature in lyophilized powder.
Quality Level
Research grade
Applications
Amuvatinib hydrochloride serves as a c-Ret inhibitor used in researching targeted cancer therapies, particularly for tumors with c-Ret mutations.
Storage
Store at -20ºC, and keep desiccated.
